Outcome assessments
bleeding, organ damage, ADAMTS13
EVENTS, BLEEDING
The use of TPE and other medications, as well as bleeding events, platelet count, and organ damage markers, were recorded daily until the end of TPE, weekly until the end of the study, and at the first and last follow-up visits. In addition, the Standardized Mini-Mental State Examination (SMMSE) [With regards to caplacizumab pharmacokinetics, total caplacizumab plasma concentrations were evaluated on Days 2 and 3, then weekly thereafter. Pharmacodynamic parameters (i.e., VWF:Ag, FVIII:C, and VWF:RCo) were evaluated on Days 1, 2, and 3 of the daily TPE period, and then daily during the rest of the follow-up up period. ADAMTS13 activity was evaluated on Day 1 of the daily TPE period, then weekly until the end of the study, and at the first and last follow-up visits. A description of other assessments is provided in the Supplementary Methods.